Lixte Biotechnology Holdings Net Income
| LIXT Stock | USD 2.95 0.07 2.32% |
As of the 8th of February, Lixte Biotechnology secures the Standard Deviation of 4.47, mean deviation of 3.44, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lixte Biotechnology, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Lixte Biotechnology's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lixte Biotechnology's valuation are summarized below:There are currently one hundred twenty fundamental ratios for Lixte Biotechnology that can be evaluated and compared over time across peers in the industry. All traders should check Lixte Biotechnology's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 8.8 M in 2026. Enterprise Value is likely to drop to about 3 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -3.2 M | -3.4 M | |
| Net Loss | -3.2 M | -3.4 M | |
| Net Loss | -6.1 M | -5.8 M | |
| Net Loss | (1.83) | (1.93) |
Lixte | Net Income | Build AI portfolio with Lixte Stock |
The evolution of Net Income for Lixte Biotechnology Holdings provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Lixte Biotechnology compares to historical norms and industry peers.
Latest Lixte Biotechnology's Net Income Growth Pattern
Below is the plot of the Net Income of Lixte Biotechnology Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Lixte Biotechnology financial statement analysis. It represents the amount of money remaining after all of Lixte Biotechnology Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Lixte Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (3.59 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Lixte Net Income Regression Statistics
| Arithmetic Mean | (2,891,721) | |
| Coefficient Of Variation | (63.71) | |
| Mean Deviation | 1,335,631 | |
| Median | (2,766,000) | |
| Standard Deviation | 1,842,319 | |
| Sample Variance | 3.4T | |
| Range | 6.7M | |
| R-Value | (0.70) | |
| Mean Square Error | 1.9T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | (254,105) | |
| Total Sum of Squares | 54.3T |
Lixte Net Income History
Other Fundumenentals of Lixte Biotechnology
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Lixte Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Net Income. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Lixte introduce new products? Factors like these will boost the valuation of Lixte Biotechnology. Expected growth trajectory for Lixte significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lixte Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lixte Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lixte Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Lixte Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lixte Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lixte Biotechnology.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Lixte Biotechnology on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Lixte Biotechnology Holdings or generate 0.0% return on investment in Lixte Biotechnology over 90 days. Lixte Biotechnology is related to or competes with Kairos Pharma, Lexaria Bioscience, Allarity Therapeutics, Cingulate, Briacell Therapeutics, Pulmatrix, and Entero Therapeutics. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzym... More
Lixte Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lixte Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lixte Biotechnology Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (7.45) | |||
| Potential Upside | 7.71 |
Lixte Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lixte Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lixte Biotechnology's standard deviation. In reality, there are many statistical measures that can use Lixte Biotechnology historical prices to predict the future Lixte Biotechnology's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (1.04) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lixte Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lixte Biotechnology February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (1.03) | |||
| Mean Deviation | 3.44 | |||
| Coefficient Of Variation | (866.31) | |||
| Standard Deviation | 4.47 | |||
| Variance | 20.0 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (1.04) | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (7.45) | |||
| Potential Upside | 7.71 | |||
| Skewness | 0.4471 | |||
| Kurtosis | 0.05 |
Lixte Biotechnology Backtested Returns
Lixte Biotechnology has Sharpe Ratio of -0.12, which conveys that the firm had a -0.12 % return per unit of risk over the last 3 months. Lixte Biotechnology exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Lixte Biotechnology's Standard Deviation of 4.47, mean deviation of 3.44, and Risk Adjusted Performance of (0.08) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.5, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lixte Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Lixte Biotechnology is expected to be smaller as well. At this point, Lixte Biotechnology has a negative expected return of -0.52%. Please make sure to verify Lixte Biotechnology's potential upside and day median price , to decide if Lixte Biotechnology performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.46 |
Average predictability
Lixte Biotechnology Holdings has average predictability. Overlapping area represents the amount of predictability between Lixte Biotechnology time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lixte Biotechnology price movement. The serial correlation of 0.46 indicates that about 46.0% of current Lixte Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | 0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.1 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Lixte Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Lixte Biotechnology Holdings reported net income of (3.59 Million). This is 101.05% lower than that of the Biotechnology sector and 105.12% lower than that of the Health Care industry. The net income for all United States stocks is 100.63% higher than that of the company.
Lixte Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.Lixte Biotechnology is currently under evaluation in net income category among its peers.
Lixte Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lixte Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lixte Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Lixte Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Lixte Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Lixte Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lixte Biotechnology's value.| Shares | Hightower Advisors, Llc | 2025-06-30 | 99.4 K | Citadel Advisors Llc | 2025-06-30 | 0.0 | Ethos Financial Group Llc | 2025-06-30 | 24.8 K | Geode Capital Management, Llc | 2025-06-30 | 20.7 K | Atlas Legacy Advisors, Llc | 2025-06-30 | 13.8 K | Tower Research Capital Llc | 2025-06-30 | 3.3 K | Ubs Group Ag | 2025-06-30 | 1.1 K | Sbi Securities Co Ltd | 2025-06-30 | 205 | Bank Of America Corp | 2025-06-30 | 122 | Clear Street Llc. | 2025-06-30 | 100.0 | Tiaa Trust National Association | 2025-03-31 | 0.0 |
Lixte Fundamentals
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 23.06 M | ||||
| Shares Outstanding | 8.7 M | ||||
| Shares Owned By Insiders | 0.93 % | ||||
| Shares Owned By Institutions | 9.90 % | ||||
| Number Of Shares Shorted | 108.46 K | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 10.96 X | ||||
| EBITDA | (3.57 M) | ||||
| Net Income | (3.59 M) | ||||
| Cash And Equivalents | 7.74 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 318.28 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.10 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (3.16 M) | ||||
| Short Ratio | 1.33 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 25.67 M | ||||
| Total Asset | 1.15 M | ||||
| Retained Earnings | (52.07 M) | ||||
| Working Capital | 827.22 K | ||||
| Current Asset | 1.38 M | ||||
| Current Liabilities | 140 K | ||||
| Net Asset | 1.15 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.